Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) posted quarterly EBT Margin of 50.27% for Q2 2024, up 474277.0% year-over-year from N/an in Q3 2023, and up 101.02% quarter-over-quarter from 4949.03% in Q4 2023.
Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EBT Margin for 5 consecutive years, with 50.27% the latest figure, recorded in Q2 2024.
- In Q2 2024, EBT Margin rose 474277.0% year-over-year to 50.27%; the TTM figure through Jun 2025 stood at 163.85% (down 3107.0% YoY), while the FY2024 annual figure was 91.73%, up 969387.0% from the prior year.
- EBT Margin rose to 50.27% in Q2 2024 per FULC's latest filing, from 4949.03% in the prior quarter.
- Across five years, EBT Margin topped out at 50.27% in Q2 2024 and bottomed at 14191.19% in Q1 2023.
- Historically, EBT Margin has averaged 3453.14% across 5 years, with a median of 2663.44% in 2022.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 1056477 bps — and 2024, when it soared 474277 bps.
- Fulcrum Therapeutics' EBT Margin stood at 421.8% in 2020, then plunged by 455 bps to 2342.8% in 2021, then plunged by 86 bps to 4358.86% in 2022, then decreased by 14 bps to 4949.03% in 2023, then soared by 101 bps to 50.27% in 2024.
- Business Quant data shows FULC's EBT Margin at 50.27% in Q2 2024, 4949.03% in Q4 2023, and 5304.35% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 50.27% |
| Dec 31, 2023 | -4,949.03% |
| Sep 30, 2023 | -5,304.35% |
| Jun 30, 2023 | -3,483.18% |
| Mar 31, 2023 | -10,346.78% |
| Dec 31, 2022 | -28,095.77% |
| Sep 30, 2022 | -2,289.43% |
| Jun 30, 2022 | -1,883.21% |
| Mar 31, 2022 | -3,626.42% |
| Dec 31, 2021 | -1,007.34% |
| Sep 30, 2021 | -1,954.77% |
| Jun 30, 2021 | -867.11% |
| Mar 31, 2021 | -477.82% |
| Dec 31, 2020 | -421.80% |
| Sep 30, 2020 | -2,120.94% |
| Jun 30, 2020 | -1,707.39% |
| Mar 31, 2020 | -5,337.87% |